Skip to content
‹ Back to IndustriesSciences

Chaperones Aren’t Just for the Prom: Key Step In Viral Replication Identified

Researchers at Children's Hospital of Pittsburgh have identified a key step in viral replication involving molecular chaperones, proteins that assist in the final stages of protein folding and virus assembly. This discovery advances scientific understanding of how viruses complete their construction inside host cells. The findings could open new avenues for antiviral therapies targeting this stage of the viral lifecycle.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share

Key takeaways

01

Molecular chaperones play a critical role in the final stages of viral protein folding and assembly.

02

Researchers at Children's Hospital of Pittsburgh identified this key step in viral replication.

03

Understanding this mechanism could inform the development of new antiviral treatments.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Viruses are cellular parasites that reproduce themselves by hijacking the machinery of the cells they infect. We have significant knowledge regarding cell infection and virus reproduction of themselves within cells, but scarce is our understanding of the final stages of protein folding and virus construction. However, according to SciTechDaily, researchers at Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have published a report in Nature Microbiology revealing how the proteins of the common, normally harmless reovirus, are properly folded by the cell to produce the final viruses. 

The key is the common chaperonin protein complex, TriC. A given protein can potentially fold multiple ways, but the chaperonins help proteins in the cell to fold properly. In fact, it helps fold up to 10% of all the cell’s proteins, including important proteins such as cellular cytoskeleton proteins and cell cycle regulators. TriC is highly conserved across species, indicating its importance in proper protein folding and function. This conserved structure also suggests that TriC might be a common protein for viruses to use. 

The TriC helps the reovirus’s outer capsid proteins to fold such that they can assemble into virus particles capable of being released from the cell to infect new cells. Given the central role of TriC in properly folding reovirus proteins, scientists may find ways to inhibit the folding process. However, given the central importance of TriC as a chaperonin for 10% of the cell’s proteins, therapies must be conducted carefully to avoid damage to the cells themselves. 

Whether new therapies can be developed or not, understanding the roles of chaperonins like TriC is an important step to understanding the virus lifecycle. The more we understand about how viruses take over the cellular structure, the closer we are to understanding how to therapeutically fight these miniscule cellular parasites.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512